The annual conference of the CTrials, the Israeli Association for the advancement of the biomedical research community and clinical trials in Israel, was held on April 3rd in The Chaim Sheba Medical Center Elections for the Management Committee of C-Trials were performed and Dr. Ornit Yanai-Kohelet, who presented her nomination for the committee on the morning of the elections was voted for, among with another 14 members. We believe that the current nominated committee will act to support changes to the complicated Israeli regulations and are hopeful to significantly improve and advance Clinical Trials in Israel (Hebrew). The Israeli annual conference for Clinical Trialswill be held on April 29th in DavidIntercontinental hotel in Tel Aviv. Clinical research undergoes significant changes in domestic and engaged in this field need to be revised to meet the new regulatory standards. At this conference we will refer to a variety of relevant disciplines in the field, including practical workshop management tools based GCP clinical trial, relating to the requirements of the latest health authorities in Israel and abroad. The conference is intended for all engaged in clinical trials in Israel. Israeli Teva pharmaceuticals launch generic breast cancer, osteoporosis drug. Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million. Teva has received approval from the US Food and Drug Administration (FDA) to market the generic equivalent to 60 mg Evista (Raloxifene) tablets. Teva was first to file, making the product eligible for 180 days of marketing exclusivity, and the company will begin shipping the product within the next 30 days. Robot developed by Israel's Mazor Robotics used in first brain procedure. Dr. Nizam Razack successfully performed the world’s first deep brain stimulation (DBS) using the system at Celebration Health Hospital in Orlando, Florida. Mazor Robotics announced the first use of its Renaissance robotic guidance system in brain surgery. Israeli local biomed sees future in hi-tech. The future of Israel’s biomed and life-sciences industry lies in the hi-tech world, according to industry leaders. “As you look at the mega-trends and the things that influence us, one of the most notable ones is the future of digital health care,” Yoav Chelouche, managing partner at Aviv Venture Capital, told The Jerusalem Post in a recent interview. More than 90 Israeli companies are involved in some way in the issues of digital health, he said, including wearable sensors, remote monitors for patients with chronic illnesses, medication- adherence software and 3-D printing of custom-made prosthetics. Israel's Technion ranked one of world's top 100 universities. The Technion is the only Israeli institute to make it into the world’s top 100 universities listed by the Times Higher Education World University Rankings (whose website says it is “powered by Thomson Reuters”) this year. With nine other universities, it is ranked 91st to 100th.